Literature DB >> 22478974

Are the Results of the RE-LY Trial Reliable?

Matthew P Tsang1, Aaron Tejani, I Fan Kuo.   

Abstract

Year:  2010        PMID： 22478974      PMCID： PMC2858509          DOI： 10.4212/cjhp.v63i2.908

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  3 in total

1.  Non-inferiority trials: determining whether alternative treatments are good enough.

Authors:  Ian A Scott
Journal:  Med J Aust       Date:  2009-03-16       Impact factor: 7.738

2.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

3.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245
  3 in total
  1 in total

1.  Explaining the RE-LY Trial.

Authors:  John W Eikelboom; Stuart J Connolly
Journal:  Can J Hosp Pharm       Date:  2010-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.